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Abstract
Objective To use the rs1229984 variant in the alcohol dehydrogenase
1B gene (ADH1B) as an instrument to investigate the causal role of
alcohol in cardiovascular disease.
Design Mendelian randomisation meta-analysis of 56 epidemiological
studies.
Participants 261 991 individuals of European descent, including 20 259
coronary heart disease cases and 10 164 stroke events. Data were
available on ADH1B rs1229984 variant, alcohol phenotypes, and
cardiovascular biomarkers.
Main outcome measures Odds ratio for coronary heart disease and
stroke associated with the ADH1B variant in all individuals and by
categories of alcohol consumption.
Results Carriers of the A-allele of ADH1B rs1229984 consumed 17.2%
fewer units of alcohol per week (95% confidence interval 15.6% to
18.9%), had a lower prevalence of binge drinking (odds ratio 0.78 (95%
CI 0.73 to 0.84)), and had higher abstention (odds ratio 1.27 (1.21 to
1.34)) than non-carriers. Rs1229984 A-allele carriers had lower systolic
blood pressure (−0.88 (−1.19 to −0.56) mm Hg), interleukin-6 levels
(−5.2% (−7.8 to −2.4%)), waist circumference (−0.3 (−0.6 to −0.1) cm),
and body mass index (−0.17 (−0.24 to −0.10) kg/m2). Rs1229984 A-allele
carriers had lower odds of coronary heart disease (odds ratio 0.90 (0.84
to 0.96)). The protective association of the ADH1B rs1229984 A-allele
variant remained the same across all categories of alcohol consumption
(P=0.83 for heterogeneity). Although no association of rs1229984 was
identified with the combined subtypes of stroke, carriers of the A-allele
had lower odds of ischaemic stroke (odds ratio 0.83 (0.72 to 0.95)).
Conclusions Individuals with a genetic variant associated with
non-drinking and lower alcohol consumption had a more favourable
cardiovascular profile and a reduced risk of coronary heart disease than
those without the genetic variant. This suggests that reduction of alcohol
consumption, even for light to moderate drinkers, is beneficial for
cardiovascular health.
Introduction
Alcohol is the fifth leading risk factor for death and disability
accounting for 4% of life years lost due to disease.1 While the
harmful effects of alcohol on conditions such as liver cirrhosis,
injuries, and cancers of the liver, colorectum, breast, and upper
aerodigestive tract have been firmly established,2 uncertainty
remains concerning the potential protective effects of light to
moderate alcohol consumption on risk of coronary heart disease
and stroke.3-5 Observational studies have consistently reported
that compared with non-drinkers, light to moderate drinking
exhibits a reduced cardiovascular risk,6 7 with the lowest risk
found at approximately 12-25 British units per week, while
heavier and more hazardous drinking is associated with an
increased risk, resulting in the well established U shaped
association.2 8 However, the apparent cardioprotective effect
associated with light to moderate drinking could be explained
by an elevated cardiovascular risk from underlying poor health
in non-drinkers,9 or confounding by lifestyle or social factors
associated with light to moderate drinking.10
The most widely proposed mechanism for this purported
cardioprotective effect of alcohol is an increase in high density
lipoprotein (HDL) cholesterol.11 However, the causal nature of
the association of HDL cholesterol with cardiovascular events
is unclear.12 13 Although an HDL cholesterol raising effect of
alcohol has been reported in experimental studies,11 the small
sample size and short follow-up means existing studies may be
prone to bias, undermining their validity.
In the absence of a viable randomised trial to confirm or refute
the cardioprotective effect of light to moderate alcohol
consumption, an alternative approach is to use a genetic variant
that serves as a proxy for alcohol consumption. This approach,
known as Mendelian randomisation, avoids some of the key
limitations of observational studies, since allocation of genetic
variants is random with regard to potential confounders, and
genotype is not modified by disease (abolishing reverse
causality).14 15 A non-synonymous single nucleotide
polymorphism (rs1229984) in the alcohol dehydrogenase 1B
gene (ADH1B), which encodes the ADH1B enzyme, which
provides the primary pathway of alcohol metabolism,16 has been
associated with a flush response to alcohol consumption, lower
levels of usual alcohol consumption and blood ethanol levels,17
as well as a lower risk of alcohol dependence among adult
drinkers18 19 and adolescents,19 which led to the selection of this
single nucleotide polymorphism as a genetic instrument in
previousMendelian randomisation studies that investigated the
role of alcohol in high blood pressure and various cancers.20-23
We present results from an international collaboration that used
the ADH1B rs1229984 variant as an instrument to investigate
the association of alcohol with cardiovascular biomarkers and
events in more than 260 000 individuals.
Correspondence to: J P Casas, Faculty of Epidemiology and Public Health, London School of Hygiene & Tropical Medicine, London WC1E 7HT,
UK Juan-P.Casas@lshtm.ac.uk
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Methods
Formation of the consortium
Given that the rs1229984 genetic variant is not represented in
widely available genotyping platforms such as
Illumina-metabochip, Illumina-immunochip, or genome-wide
association platforms (with the exception of recent platforms),
we initially focused on studies genotyped with the IBC
Cardiochip array, which contains this single nucleotide
polymorphism (SNP). Through contact with the designer of the
Institute for Translational Medicine and Therapeutics (ITMAT)
Broad Institute CARe consortium (IBC) CardioChip array (B
J Keating,24 coauthor), we contacted all population based studies
genotyped on this array. Subsequently, we established contact
with a series of genetic study groups with whom we have
collaborated in the past and sent them a brief proposal describing
the general aims of the study, including de novo genotyping in
their studies. A minor subset of studies in European descent
population that used this variant in previous publications was
also identified and included in the consortium (details available
in table S1 in the appendix on bmj.com). In addition, we checked
publicly available consortia such as CARDIoGRAMplusC4D
(www.cardiogramplusc4d.org) and found the SNP was not
included in these consortia.
We incorporated individual participant data from 261 991
participants of European ancestry from 56 studies (see
appendix). All participants provided written, informed consent,
and ethical approval was granted by local ethics committees for
participating studies. Ethical approval for secondary data
analysis was granted by the London School of Hygiene &
Tropical Medicine ethics committee (application No 5905).
Alcohol traits
The principal alcohol trait was weekly volume of alcohol in
British units (1 British unit is equivalent to 0.57 US units or 10
ml (7.9 g) ethanol), which we derived using questionnaire data
from each study (table S2 in the appendix). We additionally
assessed the overall drinking status (drinkers v non-drinker) of
study subjects, the study specific top tertile of alcohol
consumption (separately for men and women), and history of
binge drinking (for details see supplementary methods 2.1).
γ-glutamyltransferase was used as a marker of heavy alcohol
consumption.
Clinical outcomes
The primary clinical event was incident and prevalent (including
fatal and non-fatal) coronary heart disease. Secondary clinical
outcomes were stroke and type 2 diabetes. Stroke included all
subtypes and consisted of incident and prevalent (including fatal
and non-fatal) cases. In a subsample, information on ischaemic
stroke was also available. For type 2 diabetes, we restricted the
analysis to prevalent cases with the exception of one nested
case-cohort that included incident cases.25 Precise definitions
of outcomes for each study are reported in table S3 of the
appendix.
Genotype properties
Genotyping platforms, genotype frequencies, Hardy Weinberg
equilibrium P values, and call rates (median of 98.8%) for
ADH1B rs1229984 (directly genotyped in all studies) are listed
in table S1 and figure S1 of the appendix.
Statistical analysis
A standard analysis protocol was applied to each study to
produce a consistent dataset. Analyses were conducted using
individual participant data in each study and then pooled across
studies using meta-analysis. Because of differences in variables
collected by each study, not all studies were included in all
analyses (fig S2 of appendix). We restricted analyses to
individuals of European descent with data forADH1B rs1229984
genotype, age, sex, and any one of the outcomes of interest. All
non-normally distributed continuous variables, including
units/week of alcohol, were natural log transformed. For these
traits, the mean difference on the logarithmic scale was
exponentiated to generate the relative difference and then
converted to a percentage difference.
We investigated the shape of the association between alcohol
consumption (log units/week) and cardiovascular biomarkers
and potential confounders in observational analysis among 131
490 individuals from 28 studies. Statistical details are given in
supplementary methods 2.2 of the appendix.
For all genetic analyses, we used a dominant model due to the
low prevalence of the rs1229984 A-allele (average carriage of
rs1229984 A-alleles: 7%): data from carriers of either one or
two rare A-alleles were pooled and compared with individuals
homozygous for the G-allele (the reference group). We first
quantified the effects of rs1229984 A-allele on alcohol traits as
well as on lifestyle and social factors to validate our instrument
for alcohol consumption. Then, we studied the associations of
the rs1229984 A-allele with cardiovascular biomarkers from
several pathways that may mediate the effects of alcohol on
cardiovascular events. Finally, we evaluated the effects of the
rs1229984 A-allele on coronary heart disease, combined
subtypes of stroke (as well as ischaemic stroke separately) and
type 2 diabetes.
For continuous traits, means and standard deviations were
derived for rs1229984 A-allele carriers and non-carriers. For
binary traits, log odds ratios and standard errors were estimated
for rs1229984 A-allele carriers versus non-carriers. All effect
estimates were calculated within each study and then pooled
using fixed (default) and random effects meta-analysis. Between
study heterogeneity was quantified using I2.26
If the U shaped association between alcohol consumption and
cardiovascular events is real, a comparison of event rates in
rs1229984 A-allele carriers (associated with a reduction in
alcohol consumption from published studies20) versus
non-carriers will vary across broad categories of alcohol
consumption. In light to moderate drinkers (>0 to <21
units/week), ADH1B rs1229984 A-allele carriers will be
expected to have a higher coronary heart disease event risk,
whereas, for heavy drinkers (≥21 units/week) they will be
expected to have a lower event risk. Likewise, this stratification
by alcohol consumption will also serve to validate the ADH1B
rs1229984 A-allele variant as a specific instrument for alcohol
consumption, as it is expected that in non-drinkers carriage of
the rs1229984 A-allele variant will have no effect on
cardiovascular traits or events, or a substantially attenuated
effect given the known difficulty in correctly classifying long
term non-drinkers from self reported questionnaires.27Therefore,
we repeated the genetic analysis in strata of alcohol intake (none
(0 units/week), light to moderate (>0 to <21 units/week), and
heavy (≥21 units/week); the strata were selected to represent
the U shaped association of alcohol and cardiovascular events
from observational studies) and investigated if there was a trend
between alcohol categories and the effect of rs1229984 A-allele
using meta-regression (see supplementary methods 2.3 of
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appendix for further details). The same stratified analysis was
conducted for potential confounders, to investigate if
confounding was reintroduced by stratifying by alcohol.28 For
units/week of alcohol consumption (our main alcohol
phenotype), we also performed a subgroup analysis according
to the type of alcohol questionnaire (according to whether
consumption questions asked separately for beverage type (such
as beer, wine, spirits) v all beverages combined). Exploratory
subgroup analyses were undertaken to assess the impact of study
characteristics included sex, mean age, geographical region,
Hardy Weinberg equilibrium, genotype platform, year of DNA
extraction, and, whether the study contributed to observational
analysis.
In order to investigate potential residual confounding by
population stratification, we adjusted for principal components
derived from IBC CardioChip array24 in studies with available
data (see supplementary methods 2.4 for further details). To
evaluate confounding by linkage disequilibrium between
rs1229984 with single nucleotide polymorphisms associated
with cardiovascular risk factors in genome-wide association
studies29 that could distort associations of rs1229984, we used
theWhitehall-II cohort30 (including both IBC CardioChip24 and
MetaboChip31 platforms).
In the current manuscript, we did not conduct an instrumental
variable analysis to estimate causal effects since the available
methods assume a linear association between the exposure and
the outcome, which may not hold for alcohol and cardiovascular
disease.
Analyses were conducted in Stata v13.0 (StataCorp, Texas,
USA). All P values reported are two sided.
Results
We approached 59 studies, of which 56 were included in this
collaboration. Of the three excluded studies, two
(INTERHEART and INTERSTROKE) declined to participate
because of overlap with existing projects, and a third (CoLaus)
was excluded as the rs1229984 genetic variant was not directly
genotyped.
Of the 261 991 participants in our analysis, 48% were women,
and the mean age per study was 58 years (range 26-75 years)
(table S4 of appendix). The median number of alcohol units
consumed in each study is shown in table S4. There were 20
259 coronary heart disease events, 10 164 stroke cases (4339
ischaemic strokes) and 14 549 type 2 diabetes cases (table S5).
Means and distributions for continuous traits in all studies are
presented in tables S6-S8. The observational analysis between
alcohol and cardiovascular risk factors is reported in the
supplementary results section and figures S2 and S3 of the
appendix.
Genetic association analysis
ADH1B and alcohol consumption
Carriers of the rs1229984 A-allele consumed fewer units of
alcohol per week (−17.2% units/week (95% confidence interval
−18.9% to −15.6%)) and had lower odds of being in the top
third of drinking volume (odds ratio 0.70 (0.68 to 0.73))
compared with non-carriers. Rs1229984 A-allele carriers also
had lower odds of binge drinking (odds ratio 0.78 (0.73 to 0.84)),
increased odds of being self reported abstainers (odds ratio 1.27
(1.21 to 1.34)) and lower levels of γ-glutamyltransferase (−1.8%
(−3.4% to −0.3%)) (table 1⇓).
The association of the rs1229984 A-allele with alcohol volume
remained unaltered when stratified by age, gender, geographical
region, Hardy Weinberg Equilibrium P value, and whether the
alcohol questionnaire used was beverage specific (fig S4 of
appendix), or after exclusion of samples with a proportion of
A-allele carriers >10% (approximately >5% minor allele
frequency; data available on request). Ameta-regression analysis
of the mean alcohol volume (on the log scale) in rs1229984
A-allele carriers compared with non-carriers that takes into
account the uncertainty around the mean suggested a constant
proportional effect of the of ADH1B rs1229984 variant on
alcohol volume (fig S5). This was also supported by the finding
that in our samples the standard deviations for carriers and
non-carriers were very similar (fig S6).
ADH1B and cardiovascular biomarkers
Carriers of the rs1229984 A-allele had lower systolic blood
pressure (−0.88 (−1.19 to −0.56) mm Hg) compared with
non-carriers. Concordant with this, rs1229984 A-allele carriers
also had lower odds of hypertension (104 570 cases; odds ratio
0.94 (0.91 to 0.98)). Rs1229984 A-allele carriers had lower
levels of interleukin-6 (−5.2% (−7.8% to −2.4%)), C reactive
protein (−3.4% (−5.7% to −1.1%)), body mass index (−0.17
(−0.24 to −0.10) kg/m2), and waist circumference (−0.34 (−0.58
to −0.10) cm). Rs1229984 A-allele carriers also had lower
non-HDL cholesterol concentrations (−0.03 (−0.05 to −0.01)
mmol/L) (table 2⇓).
When the effect of the ADH1B rs1229984 A-allele on these
cardiovascular traits was stratified by alcohol consumption, a
differential effect was observed. Among heavy drinkers (≥21
units/week), carriers of the rs1229984 A-allele, who on average
consume 17.2% less alcohol than non-carriers, showed a more
pronounced reduction in these cardiovascular traits than that
observed in light to moderate drinkers and non-drinkers (fig
1⇓). In contrast, the effect of rs1229984 on these cardiovascular
traits did not differ systematically according to exploratory
subgroup analyses by laboratory procedures or study
characteristics (P>0.05 for 52 of 58 comparisons; fig S7 of
appendix).
Although we observed that rs1229984 A-allele carriers had
higher triglyceride levels (1.6% (0.7% to 2.6%)), this effect was
not modified by alcohol categories (fig 1⇓).
There was no overall difference between rs1229984 A-allele
carriers and non-carriers in HDL cholesterol concentration
(−0.004 (−0.012 to 0.003) mmol/L). However, an association
between rs1229984 A-allele carriage with HDL cholesterol was
observed in the highest category of alcohol consumption, but
in the opposite direction to that expected from observational
findings (0.04 (0.02 to 0.06) mmol/L; fig S8 of appendix). (That
is, the log-linear association of HDL cholesterol with alcohol
consumption from observational studies (fig S3) would suggest
that a reduction in alcohol consumption, as observed for carriers
of the rs1229984 A-allele, should associate with a reduction in
HDL cholesterol levels.) In subgroup analysis by laboratory
procedures and major study characteristics, we observed that
rs1229984 A-allele carriers from northern Europe had lower
levels of HDL cholesterol (−0.04 (−0.05 to −0.02) mmol/L).
Since this geographical specificity could reflect residual
population stratification in samples outside northern Europe,
we adjusted for principal components in a subset of individuals
not from northern Europe. The unadjusted model for the
association between rs1229984 A-allele and HDL cholesterol
(0.02 difference in standard deviation (95% confidence interval
−0.02 to 0.06)) did not differ from the model adjusted for
population structure (0.01 difference in standard deviation
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(−0.03 to 0.05)) (fig S8). Similar null results were observed for
apolipoprotein A1 (table S9 of appendix).
Rs1229984 A-allele carriage was not associated with carotid
intima medial thickness, electrocardiographic measures of left
ventricular hypertrophy, fibrinogen, von Willebrand factor,
factor VII, fasting blood glucose, N-terminal of the prohormone
brain natriuretic peptide, or lipoprotein(a) overall (table S9 of
appendix). For these traits, similar null results were observed
when stratified for alcohol consumption or by other exploratory
subgroups (P>0.05 for 47 of 48 comparisons, data available on
request), with the exception of fasting glucose and lipoprotein(a),
where the strength of association wasmore pronounced in heavy
drinkers compared with other alcohol categories (P values for
heterogeneity 0.05 and 0.01, respectively) (fig S9).
ADH1B and lifestyle factors
Carriage of the rs1229984 A-allele was not associated with
physical activity, but showed higher odds of ever smoking (odds
ratio 1.06 (95% confidence interval 1.02 to 1.09)). However,
the association with ever smoking was in the opposite direction
to that seen in observational analysis, and no association was
observed for other quantitative measures of tobacco exposure
such as cigarettes per day, pack years, or cotinine levels.
Rs1229984 A-allele carriers showed higher total years in
education (0.04 difference in standard deviation (95%
confidence interval 0.01 to 0.08)). No differential effect of
ADH1B on any of the lifestyle factors was identified on
stratifying by alcohol intake (making it unlikely that stratifying
by alcohol introduced bias) or by other exploratory subgroups
(P>0.05 for all comparisons) (figs S10 and S11 of appendix).
ADH1B and cardiovascular events
Rs1229984 A-allele carriage showed reduced odds of coronary
heart disease (odds ratio 0.90 (95% confidence interval 0.84 to
0.96, I2=17%)) (fig 2⇓ and fig S12 of appendix). In studies with
≥1000 coronary heart disease events (four studies with 8374
coronary heart disease events), the odds ratio for coronary heart
disease was 0.81 (0.72 to 0.91, I2=0%) (table S10). When
analysis was restricted to non-drinkers the association was null
(odds ratio 0.98 (0.88 to 1.10)), while among drinkers (>0
units/week alcohol), carriers of the rs1229984 A-allele had
reduced odds of coronary heart disease (odds ratio 0.86 (0.78
to 0.94)). This is consistent with the assumption that the
associations ascribed to the ADH1B variant are mainly due to
alcohol consumption. Further subdivision of the drinkers
category into light (>0 to <7 units/week), moderate (≥7 to <21
units/week), and heavy (≥21 units/week) showed the same
protective effect of the variant across all alcohol categories (P
value for heterogeneity=0.83; fig 2⇓), suggesting that there was
no difference between rs1229984 A-allele carriers and
non-carriers in coronary heart disease risk across alcohol
consumption levels among individuals who drank.
Although there was no association of the rs1229984 A-allele
with the combined stroke subtypes (odds ratio 0.98 (0.90 to
1.07)) (fig 3⇓), when the analysis was limited to ischaemic
stroke subtype, rs1229984 A-allele carriers had lower odds of
ischaemic stroke (odds ratio 0.83 (0.72 to 0.95)) (fig S13 of
appendix). No association between rs1229984 A-allele with
type2 diabetes was observed (odds ratio 1.02 (0.95 to 1.09))
(fig 3⇓).
Random effect estimates for associations of ADH1B with all
outcomes were similar to those from fixed effect models (figs
S4-14 of appendix).
Adjustment for population structure did not alter the rs1229984
A-allele associations (figs S15-16). The gene variant was not
in linkage disequilibrium with previously reported loci from
genome-wide association studies for any cardiovascular trait
(table S11).
Discussion
Principal findings of study
In this large scaleMendelian randomisation analysis, we showed
that carriers of the rs1229984 A-allele had lower levels of
alcohol consumption and exhibited lower levels of blood
pressure, inflammatory biomarkers, adiposity measures, and
non-HDL cholesterol, and reduced odds of developing coronary
heart disease, compared with non-carriers of this allele. In
contrast to previous observational and experimental studies, our
study showed that individuals with a genetic predisposition to
consume less alcohol had lower, not higher, odds of developing
coronary heart disease regardless of whether they were light,
moderate, or heavy drinkers. Moreover, ADH1B genotype was
not associated with type 2 diabetes, HDL cholesterol level, or
coagulation markers.
The rs1229984 A-allele showed very strong association with
non-drinking and amount of alcohol consumed. The fact that
our analyses suggested a constant proportional effect of the
rs1229984 A-allele on alcohol volume across a wide range of
alcohol volume from the included studies supports the notion
that social pressure in heavier drinking cultures is unlikely to
override the effect of the genetic variant on alcohol
consumption.20 It is important to note that the rs1229984A-allele
was a proxy for all types of self reported drinking behaviour
including volume, being in the top third of drinkers per study,
binge drinking, and abstention, and it also showed association
with levels of the liver enzyme γ-glutamyltransferase (an
objective marker of heavy alcohol intake). This confirms that
rs1229984 was suitable as a non-specific genetic proxy of
alcohol consumption in the mendelian randomisation analysis.
Our findings are therefore not specific to one particular type of
alcohol behaviour, but reflect a combination of different patterns
of alcohol exposures, which are nevertheless directionally
concordant (that is, the A-allele resulted in lower alcohol
consumption).
For the cardiovascular traits that showed association on overall
with the rs1229984 A-allele, null or substantially reduced
associations were observed in non-drinkers and more
pronounced associations in heavy drinkers when compared with
light to moderate drinkers. This is as expected under the
assumption that the effect of this genetic variant is only
explained by exposure to alcohol.
From the U shaped association seen in observational studies,
we would expect that for drinkers below the nadir (12-25
units/week), a reduction of 17.2% in alcohol consumption
(corresponding to rs1229984 A-allele carriage) would lead to
a small increase in the risk of coronary heart disease, whereas
for those with alcohol consumption above the nadir, a similar
reduction in alcohol consumption would lead to a decrease in
coronary heart disease risk. Contrary to these expectations,
however, we found that individuals below the nadir with a
genetic predisposition to consume less alcohol had lower odds
of developing coronary heart disease at all categories of alcohol
consumption (fig 2⇓), bringing the hypothesised cardioprotective
effect of alcohol into question.
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Strengths and weaknesses of the study
Major strengths of this international collaboration are the large
sample size, availability of detailed alcohol phenotypic data and
a comprehensive repertoire of cardiovascular risk factors and
major cardiovascular events. The process by which studies were
recruited into the collaboration, including mainly unpublished
data, means that findings are unlikely to suffer from publication
bias. The use of a standardised analytical protocol further
increases reliability of the findings.
The lack of association of the ADH1B rs1229984 A-allele with
HDL cholesterol levels was unexpected. In principle, failure to
detect an association with HDL cholesterol could have arisen
from lack of power. However, this is unlikely as rs1229984 was
associated with traits (such as C reactive protein or interleukin
6) for which alcohol consumption had a less powerful effect
and where the sample size for genetic analysis was several times
smaller than for HDL cholesterol (fig S2 of appendix). Our
extensive subgroup and in silico analyses also suggested it was
unlikely that laboratory technique, type of alcohol questionnaire
used in the studies, or confounding by linkage disequilibrium
could explain the overall null effect. We did find an association
of rs1229984 A-allele carriage with HDL cholesterol in the
subset of northern European studies. Although this suggests the
lack of association in non-northern European studies may arise
from population stratification, adjustment for population
structure using principal components analysis did not reveal an
association, making this an unlikely explanation.
We also did not identify associations of the rs1229984 A-allele
with coagulation markers, type 2 diabetes, and the combined
subtypes of stroke. With regard to coagulation markers, these
results seem more robust for fibrinogen, as confirmed by
subgroup analysis. For factor VII and von Willebrand factor,
reduced sample size limited our ability to exclude a small effect.
Although we observed an overall null association of the
rs1229984 A-allele with type 2 diabetes and blood glucose
concentration, a stratified analysis by alcohol consumption
showed that, among heavy drinkers, carriers of the rs1229984
A-allele had lower levels of glucose and a directionally
consistent relationship with type 2 diabetes. It is interesting that
we did not observe a stronger protective association of coronary
heart disease in heavy drinkers for carriers of the ADH1B
variant, as we observed for cardiovascular risk factors. This is
likely to reflect reduced power due to the low number of
coronary heart disease events in the heavy drinking stratum.
The relatively small number of stroke events is an important
limitation, as well as the use of combined stroke subtypes, which
could have obscured some differential associations of alcohol
by pathological or aetiological subtype, as suggested by recent
overviews from observational studies.7 In this context it is
interesting to note than in a subset of studies, we found the
rs1229984 A-allele associated with reduced odds of ischaemic
stroke, but this requires replication.
One of the advantages of a mendelian randomisation study is
that this design is less prone to some of the biases of
observational studies. In contrast to observational analyses that
have shown associations of alcohol with physical activity and
different measures of smoking,32 rs1229984 A-allele was not
associated with physical activity or any of the more precise
measures of smoking exposure (cigarettes/day, pack years, or
cotinine level). However, an association was observed with the
binary ever/never smoking trait, but this was in the opposite
direction to the association with coronary heart disease and is
therefore unlikely to explain the association of rs1229984
A-allele with a reduced risk of coronary heart disease. There
was also some evidence for a difference in years of education,
and, while the size of the effect was small, this requires further
investigation.
Strengths andweaknesses in relation to other
studies
Our findings compare with findings from studies in east Asians,
using the rs671 genetic variant of the aldehyde dehydrogenase
2 gene (ALDH2), that have also shown associations of alcohol
with blood pressure, bodymass index, and non-HDL cholesterol
levels.21 22However, the association with coronary heart disease
events remains unclear since the association of ALDH2 with
coronary heart disease has been analysed only in small
studies.21 22 In contrast to our findings, ALDH2 rs671 has shown
an association with HDL cholesterol levels in individuals of
Asian ancestry.21 In Europeans the ALDH2 rs671 variant is
monomorphic and cannot be used for mendelian randomisation,
and previous studies have therefore used the ADH1B genotype
to investigate the effect of alcohol on cardiovascular disease.20-34
Our results not only replicate findings of ADH1B on blood
pressure and body mass index from smaller data collections,
but expand the number of cardiovascular traits and includemajor
vascular events. Given our large sample size, we are able to
identify associations with other cardiovascular traits (non-HDL
cholesterol, interleukin 6, and C reactive protein), and most
notably we are able to detect for the first time an association
with coronary heart disease.
One feature in common to both ALDH2 and AHD1B for
mendelian randomisation is the use of genetic variants within
loci that encode alcohol metabolising enzymes. In both
examples, genetic variation results in altered exposure to
acetaldehyde, a metabolite of alcohol that causes unpleasant
symptoms, thought to be responsible for the different drinking
behaviour in individuals who possess the alleles.35Thus, a simple
interpretation of a mendelian randomisation analysis using a
genetic variant in an alcohol metabolising enzyme is that it is
akin to a long term randomised trial of more versus less alcohol
exposure.
Meaning of the study: possible explanations
and implications for clinicians and
policymakers and other researchers; how
your study could promote better decisions
These data show that individuals of European descent with a
genetic predisposition to consume less alcohol had a reduced
risk of coronary heart disease and ischaemic stroke, and lower
levels of several established and emerging risk factors for
cardiovascular disease. These findings suggest that reductions
of alcohol consumption, even for light to moderate drinkers,
may be beneficial for cardiovascular health. Our results therefore
challenge the concept of a cardioprotective effect associated
with light to moderate alcohol consumption reported in
observational studies and suggest that this effect may have been
due to residual confounding or selection bias.
Unanswered questions and future research
Although the association of the ADH1B variant with coronary
heart disease is compatible with being null in non-drinkers and
a more pronounced association is seen in drinkers, future access
to large scale population studies such as UKBiobank and China
Kadoorie Biobank Study will help to minimise potential
measurement error in alcohol exposure and provide sufficiently
large numbers of coronary heart disease events to enable
replication of our findings, in particular the analysis stratified
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by alcohol status, but will also allow a more detailed
examination of stroke subtypes.
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What is already known on this topic
Observational studies suggest that consuming alcohol in heavy amounts is deleterious for cardiovascular health, whereas light to
moderate consumption may be protective
However, findings for light to moderate drinkers could be due to unaccounted bias
What this study adds
Use of a genetic approach in an analysis of over 260 000 participants showed that carriers of a variant in the alcohol dehydrogenase
1B gene (ADH1B) associated with less alcohol consumption were found to have a reduced risk of coronary heart disease, and this was
maintained at all levels of alcohol consumption
Under the principles of mendelian randomisation, these findings suggest that reduction of alcohol consumption, even for light to moderate
drinkers, is beneficial for cardiovascular health
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Tables
Table 1| Pooled estimates of association between genetic variant ADH1B rs1229984 (A-allele carriers v non-carriers) and measures of
alcohol consumption. (Summary effect estimates are derived from fixed effects meta-analysis)
I2 value (%)P valueEffect estimate (95% CI)No of studies, cases/individualsAlcohol consumption measure
% differenceLog transformed data*
645.5×10−76−17.22 (−18.86 to −15.55)46, NA/218 969Intake volume (units/week†)
360.028−1.84 (−3.40 to −0.26)15, NA/97 755γ-glutamyltransferase level (U/L)
Odds ratioCategorical data
609.8×10−670.70 (0.68 to 0.73)45, 69 229/222 332Top tertile of alcohol intake
471.4×10−120.78 (0.73 to 0.84)21, 22 198/131 290Binge drinker‡
732.6×10−191.27 (1.21 to 1.34)32, 24 482/189 854Alcohol abstainer‡
NA = not applicable.
*Non-normally distributed variables were natural log transformed and mean differences on the log scale were converted to percentage differences.
†Alcohol units in British units; 1 UK unit = 0.57 US units or 10 mL (7.9 g) ethanol.
‡For definitions of binge drinker and alcohol abstainer, see table S2 in appendix.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2014;349:g4164 doi: 10.1136/bmj.g4164 (Published 10 July 2014) Page 13 of 16
RESEARCH
Table 2| Pooled estimates of association between genetic variant ADH1B rs1229984 (A-allele carriers v non-carriers) and cardiovascular
biomarkers in all participants. (Summary effect estimates are derived from fixed effects meta-analysis and are reported asmean differences
unless stated otherwise)
I2 value (%)P valueEffect estimate (95% CI)No of studies, individualsBiomarker
264.1×10−8−0.88 (−1.19 to −0.56)48, 227 559Systolic blood pressure (mm Hg)
Anthropometric measures:
523.4×10−6−0.17 (−0.24 to −0.10)51, 232 570Body mass index (weight (kg)/(height (m)2))
416.2×10−3−0.34 (−0.58 to −0.10)42, 140 923Waist circumference (cm)
Inflammation:
332.90×10−4−5.15 (−7.82 to −2.40)17, 30 950Log transformed interleukin 6 (% difference)*
14.60×10−3−3.40 (−5.68 to −1.05)42, 124 498Log transformed C reactive protein (% difference)*
Lipids:
255.10×10−3−0.03 (−0.05 to −0.01)46, 202 794Non-HDL cholesterol (mmol/L)
368.90×10−41.61 (0.66 to 2.57)46, 205 824Log transformed triglycerides (% difference)*
540.259−0.004 (−0.012 to 0.003)46, 203 440HDL cholesterol (mmol/L)
*Non-normally distributed variables were natural log transformed and mean differences on the log scale were converted to percentage differences.
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Figures
Fig 1 Meta-analysis pooled estimates of the association between ADH1B rs1229984 (A-allele carriers v non-carriers) and
cardiovascular disease biomarkers showing association on crude analysis, stratified by alcohol intake
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Fig 2 Meta-analysis pooled estimates of the association between ADH1B rs1229984 (A-allele carriers v non-carriers) and
coronary heart disease overall, and stratified by alcohol intake
Fig 3 Meta-analysis pooled estimates of the association between ADH1B rs1229984 (A-allele carriers v non-carriers) and
stroke (combined subtypes) and type 2 diabetes overall, and stratified by alcohol intake
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